EE693 Assessing the Impact of Additional Follow-up From the CheckMate-274 Trial on the Cost-Effectiveness (CE) Profile of Nivolumab Versus Surveillance in High-Risk, Muscle-Invasive Urothelial Carcinoma (MIUC)
Abstract
Authors
T. Chandler I. Orsini C. Van Beurden-Tan M. Kurt M. Patel S. Teitsson